Bone Growth Stimulator Market to be Worth $1.8B by 2027

The global bone growth stimulator market is primed for solid growth over the next four years.

Markets and Markets projects the sector to expand 5.9% annually to reach $1.8 billion in value by 2027. Growth drivers include the rising number of orthopedic conditions; higher demand for bone growth stimulators in spinal fusion surgeries, delayed union and nonunion bone fractures applications; and more overall demand for bone growth stimulator devices.
 
On a product type basis, the market is segmented into bone growth stimulation devices, bone morphogenetic proteins (BMPs), and platelet-rich plasma (PRP). The bone growth stimulation devices segment accounted for the largest market share in 2021 due to an aging world population, a greater preference for non-surgical treatment procedures, and the rising prevalence of nonunion fractures.
 
By application, the market is broadly segmented into spinal fusion surgeries, delayed union and nonunion bone fractures, oral and maxillofacial surgeries, and other applications. In 2021, the spinal fusion surgeries applications segment dominated the market, thanks to an increasing number of spinal fusion and maxillofacial surgeries across various regions. 
 
Based on end user, the market is categorized into hospitals and ambulatory surgery centers (ASCs), home care settings, and academic and research institutes. The hospitals and ambulatory surgical centers segment accounted for the largest market share in 2021 due to a rising patient population, increasing prevalence of spinal disorders, greater spinal fusion surgery volume, rising awareness of bone growth stimulation products, and an increasing number of new hospitals and ASCs worldwide.
 
The global bone growth stimulators market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market was most dominant in 2021 as spinal fusion surgeries, delayed union, and nonunion bone fractures procedures increased, and demand rose for bone growth stimulator devices.
 
The market’s major players are Orthofix Medical Inc., Enovis, ZimVie, Bioventus LLC, Medtronic plc, Stryker Corp., DePuy Synthes, Arthrex Inc., Isto Biologics, Ember Therapeutics Inc., Ossatec Benelux Ltd., Altis Biologics Pty. Ltd., Regen Lab SA, ITO Co. Ltd., Elizur Corporation, BTT Health GmbH, Stimulate Health, VQ OrthoCare, and Kinex Medical Company LLC.